Taisho Pharmaceutical Holdings Co (TSE:4581) Total Liabilities : 円148,168 Mil (As of Dec. 2023)

View and export this data going back to 2011. Start your Free Trial

What is Taisho Pharmaceutical Holdings Co Total Liabilities?

Taisho Pharmaceutical Holdings Co's Total Liabilities for the quarter that ended in Dec. 2023 was 円148,168 Mil.

Taisho Pharmaceutical Holdings Co's quarterly Total Liabilities increased from Jun. 2023 (円141,931.00 Mil) to Sep. 2023 (円143,810.00 Mil) and increased from Sep. 2023 (円143,810.00 Mil) to Dec. 2023 (円148,168.00 Mil).

Taisho Pharmaceutical Holdings Co's annual Total Liabilities increased from Mar. 2021 (円118,519.00 Mil) to Mar. 2022 (円120,202.00 Mil) and increased from Mar. 2022 (円120,202.00 Mil) to Mar. 2023 (円132,147.00 Mil).

Taisho Pharmaceutical Holdings Co Total Liabilities Historical Data

The historical data trend for Taisho Pharmaceutical Holdings Co's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Taisho Pharmaceutical Holdings Co Total Liabilities Chart

Taisho Pharmaceutical Holdings Co Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Total Liabilities

Get a 7-Day Free Trial

97,647.00

125,197.00

118,519.00

120,202.00

132,147.00

Taisho Pharmaceutical Holdings Co Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Total Liabilities	Get a 7-Day Free Trial															131,286.00	132,147.00	141,931.00	143,810.00	148,168.00

Taisho Pharmaceutical Holdings Co Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Taisho Pharmaceutical Holdings Co's Total Liabilities for the fiscal year that ended in Mar. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	73778	+	(0	+	38501
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	19868)
	=	132,147

Total Liabilities	=	Total Assets (A: Mar. 2023 )	-	Total Equity (A: Mar. 2023 )
	=	941490	-	809343
	=	132,147

Taisho Pharmaceutical Holdings Co's Total Liabilities for the quarter that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	80824	+	(0	+	50258
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	17086)
	=	148,168

Total Liabilities	=	Total Assets (Q: Dec. 2023 )	-	Total Equity (Q: Dec. 2023 )
	=	1005463	-	857295
	=	148,168

Taisho Pharmaceutical Holdings Co Total Liabilities Related Terms

Thank you for viewing the detailed overview of Taisho Pharmaceutical Holdings Co's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Taisho Pharmaceutical Holdings Co (TSE:4581) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Taisho Pharmaceutical Holdings Co Ltd (TSE:4581) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

TAIPY:USA TAISF:USA

Address

3-24-1 Takada, Toshima-ku, Tokyo, JPN, 170-8655

Website

http://www.taisho-holdings.co.jp

Taisho Pharmaceutical Holding Co Ltd is a specialty and generic drug manufacturing company. The company maintains two operational segments, Self-Medication and Prescription Pharmaceuticals. The vast majority of Taisho's revenue is derived from its Self-Medication segment. The company considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities. The vast majority of sales are generated by sales to external customers in Japan.

Taisho Pharmaceutical Holdings Co (TSE:4581) Headlines

No Headlines